keyword
Keywords Evaluation of no evidence of d...

Evaluation of no evidence of disease activity in a 7 year

https://read.qxmd.com/read/37883081/sustained-survival-benefit-in-recurrent-medulloblastoma-by-a-metronomic-antiangiogenic-regimen-a-nonrandomized-controlled-trial
#21
MULTICENTER STUDY
Andreas Peyrl, Monika Chocholous, Magnus Sabel, Alvaro Lassaletta, Jaroslav Sterba, Pierre Leblond, Karsten Nysom, Ingrid Torsvik, Susan N Chi, Thomas Perwein, Neil Jones, Stefan Holm, Per Nyman, Helena Mörse, Anders Öberg, Liesa Weiler-Wichtl, Ulrike Leiss, Christine Haberler, Maresa T Schmook, Lisa Mayr, Karin Dieckmann, Marcel Kool, Johannes Gojo, Amedeo A Azizi, Nicolas André, Mark Kieran, Irene Slavc
IMPORTANCE: Medulloblastoma recurrence in patients who have previously received irradiation has a dismal prognosis and lacks a standard salvage regimen. OBJECTIVE: To evaluate the response rate of pediatric patients with medulloblastoma recurrence using an antiangiogenic metronomic combinatorial approach (Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial [MEMMAT]). DESIGN, SETTING, AND PARTICIPANTS: This phase 2, investigator-initiated, multicenter nonrandomized controlled trial assessed 40 patients with relapsed or refractory medulloblastoma without a ventriculoperitoneal shunt who were younger than 20 years at original diagnosis...
December 1, 2023: JAMA Oncology
https://read.qxmd.com/read/37852737/phase-ii-trial-of-nivolumab-and-metformin-in-patients-with-treatment-refractory-microsatellite-stable-metastatic-colorectal-cancer
#22
JOURNAL ARTICLE
Mehmet Akce, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L Shaib, Christina Wu, Olatunji B Alese, Maria Diab, Gregory B Lesinski, Bassel F El-Rayes
BACKGROUND: Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that metformin with nivolumab would elicit potent antitumor and immune modulatory activity in metastatic microsatellite stable (MSS) colorectal cancer (CRC). We evaluated this hypothesis in a phase II study. METHODS: Nivolumab (480 mg) was administered intravenously every 4 weeks while metformin (1000 mg) was given orally, two times per day following a 14-day metformin only lead-in phase...
October 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37844598/pembrolizumab-plus-lenvatinib-in-second-line-and-third-line-patients-with-pleural-mesothelioma-pemmela-a-single-arm-phase-2-study
#23
JOURNAL ARTICLE
Li-Anne H Douma, Ferry Lalezari, Vincent van der Noort, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A Burgers, Cornedine J de Gooijer
BACKGROUND: The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical studies in solid tumours. We assessed the clinical activity of this combination therapy in patients with pleural mesothelioma who progressed after platinum-pemetrexed chemotherapy. METHODS: In this single-arm, single-centre, phase 2 study, done at the Netherlands Cancer Institute in Amsterdam, The Netherlands, eligible patients (aged ≥18 years) with pleural mesothelioma with an Eastern Cooperative Oncology Group performance status of 0-1, progression after chemotherapy (no previous immunotherapy), and measurable disease according to the modified Response Evaluation Criteria In Solid Tumours (mRECIST) for mesothelioma version 1...
November 2023: Lancet Oncology
https://read.qxmd.com/read/37792757/high-density-lipoprotein-cholesterol-and-systemic-arterial-hypertension-are-associated-with-hepatic-necroinflammatory-activity-in-patients-with-chronic-hepatitis-c
#24
JOURNAL ARTICLE
Gustavo Henrique De Puy E Souza, Luciana Diniz Silva, Diego Alves Vieira, Gifone Aguiar Rocha, Agnaldo Soares Lima, Paula Vieira Teixeira Vidigal
•HDL cholesterol levels <60 mg/dL were independently associated with necroinflammatory activity in chronic hepatitis C (CHC). •CHC patients with hypertension are at an increased risk of developing necroinflammatory activity. •In patients with CHC, liver fibrosis was independently associated with old age, steatosis, and HDL-C <60 mg/dL. •Triglycerides levels ≥150 mg/dL were associated with lobular inflammatory activity in patients with CHC. Background - Approximately 71 million people are chronically infected with hepatitis C virus (HCV) worldwide...
2023: Arquivos de Gastroenterologia
https://read.qxmd.com/read/37785614/correlation-of-post-treatment-biopsy-and-fluorodeoxyglucose-pet-ct-findings-following-definitive-chemotherapy-and-radiation-for-cervical-cancer
#25
JOURNAL ARTICLE
M K Hoang, J Donald, A Hoover
PURPOSE/OBJECTIVE(S): Concurrent chemotherapy and external beam radiation with brachytherapy boost is considered standard of care for treatment of locally advanced cervical cancer. Post treatment surveillance fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging is recommended 3-6 months after completion of therapy. Persistent FDG avidity is commonly observed at the cervix on surveillance scans, indeterminate for residual malignancy versus post treatment inflammatory change...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37784584/final-results-from-a-prospective-randomized-pilot-trial-of-stereotactic-body-radiation-therapy-vs-radiofrequency-ablation-for-the-management-of-small-renal-masses-radster
#26
JOURNAL ARTICLE
A Swaminath, R Cassim, B Millan, O Mironov, P Ahir, C Tajzler, J Hoogenes, K Quan, E Matsumoto, A Kapoor
PURPOSE/OBJECTIVE(S): The benefits of stereotactic body radiation therapy (SBRT) as a primary treatment modality for small renal masses (SRMs) ≤4cm are unclear. Our objective was to evaluate both SBRT and radiofrequency ablation (RFA) for SRMs to determine the utility of a future Phase III randomized controlled trial (RCT). MATERIALS/METHODS: Patients with SRMs who declined active surveillance, surgery or were deemed inoperable were recruited at a single tertiary academic center...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37781954/vaccines-for-preventing-herpes-zoster-in-older-adults
#27
REVIEW
Juliana de Oliveira Gomes, Anna Mz Gagliardi, Brenda Ng Andriolo, Maria Regina Torloni, Regis B Andriolo, Maria Eduarda Dos Santos Puga, Eduardo Canteiro Cruz
BACKGROUND: Herpes zoster, commonly known as shingles, is a neurocutaneous disease caused by the reactivation of the virus that causes varicella (chickenpox). After resolution of the varicella episode, the virus can remain latent in the sensitive dorsal ganglia of the spine. Years later, with declining immunity, the varicella zoster virus (VZV) can reactivate and cause herpes zoster, an extremely painful condition that can last many weeks or months and significantly compromise the quality of life of the affected person...
October 2, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/37769430/prevalence-of-2-year-no-evidence-of-disease-activity-neda-3-and-neda-4-in-relapsing-remitting-multiple-sclerosis-a-real-world-study
#28
JOURNAL ARTICLE
V Bazzurri, A Fiore, E Curti, E Tsantes, A Franceschini, F Granella
BACKGROUND: No evidence of disease activity (NEDA) is becoming a gold standard in the evaluation of disease modifying therapies (DMT) in relapsing-remitting multiple sclerosis (RRMS). NEDA-3 status is the absence of relapses, new activity on brain MRI, and disability progression. NEDA-4 meets all NEDA-3 criteria plus lack of brain atrophy. OBJECTIVE: Aim of this study was to investigate the prevalence of two-year NEDA-3, NEDA-4, six-month delayed NEDA-3 (6mdNEDA-3), and six-month delayed NEDA-4 (6mdNEDA-4) in a cohort of patients with RRMS...
November 2023: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/37768658/anti-tigit-antibody-tiragolumab-alone-or-with-atezolizumab-in-patients-with-advanced-solid-tumors-a-phase-1a-1b-nonrandomized-controlled-trial
#29
JOURNAL ARTICLE
Tae Won Kim, Philippe L Bedard, Patricia LoRusso, Michael S Gordon, Johanna Bendell, Do-Youn Oh, Myung-Ju Ahn, Elena Garralda, Sandra P D'Angelo, Jayesh Desai, F Stephen Hodi, Zev Wainberg, Jean-Pierre Delord, Phillippe A Cassier, Andrés Cervantes, Marta Gil-Martin, Benjamin Wu, Namrata S Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond Meng, Byoung Chul Cho
IMPORTANCE: Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1-selected tumors. OBJECTIVE: To evaluate the safety and antitumor activity of the anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors. DESIGN, SETTING, AND PARTICIPANTS: The GO30103 open-label, first-in-human phase 1a/1b dose-escalation and dose-expansion nonrandomized controlled trial was conducted at 13 sites in 6 countries (Australia, Canada, France, Korea, Spain, and the US)...
September 28, 2023: JAMA Oncology
https://read.qxmd.com/read/37748927/haematopoietic-stem-cell-transplantation-for-treatment-of-relapsing-remitting-multiple-sclerosis-in-sweden-an-observational-cohort-study
#30
JOURNAL ARTICLE
Thomas Silfverberg, Christina Zjukovskaja, Per Ljungman, Adjmal Nahimi, Erik Ahlstrand, Arta Dreimane, Sigrun Einarsdottir, Jan Fagius, Ellen Iacobaeus, Hans Hägglund, Niclas Lange, Stig Lenhoff, Jan Lycke, Johan Mellergård, Fredrik Piehl, Anders Svenningsson, Andreas Tolf, Honar Cherif, Kristina Carlson, Joachim Burman
BACKGROUND: A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS), but it has not yet been integrated into most national clinical guidelines. The objective of this study was to assess efficacy and safety when aHSCT is implemented in routine healthcare. METHODS: We assessed 231 patients and the final analysis included 174 RRMS patients who were treated with aHSCT in Sweden before 1 January 2020...
September 25, 2023: Journal of Neurology, Neurosurgery, and Psychiatry
https://read.qxmd.com/read/37748882/pretreatment-neurofilament-light-chain-serum-levels-early-disease-severity-and-treatment-response-in-pediatric-multiple-sclerosis
#31
JOURNAL ARTICLE
Brenda Huppke, Marie-Christine Reinert, Hannah Hummel-Abmeier, Wiebke Stark, Jutta Gärtner, Peter Huppke
BACKGROUND AND OBJECTIVES: High disease activity and frequent therapy failure in pediatric multiple sclerosis (MS) make prognostic biomarkers urgently needed. We investigated whether serum neurofilament light chain (sNfL) levels in treatment-naive pediatric patients with MS are associated with early disease severity and indicate treatment outcomes. METHODS: A retrospective cohort study of patients seen in the Göttingen Center for MS in Childhood and Adolescence, Germany...
November 7, 2023: Neurology
https://read.qxmd.com/read/37743037/vedolizumab-adalimumab-and-methotrexate-combination-therapy-in-crohn-s-disease-explorer
#32
JOURNAL ARTICLE
Jean-Frederic Colombel, Ryan C Ungaro, Bruce E Sands, Corey A Siegel, Douglas C Wolf, John F Valentine, Brian G Feagan, Blue Neustifter, Harisha Kadali, Pradeep Nazarey, Alexandra James, Vipul Jairath, Rana M Qasim Khan
BACKGROUND & AIMS: Although biologics have revolutionized the treatment of Crohn's disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates. METHODS: EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, and then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2, then 40 mg every 2 weeks), and methotrexate (15 mg weekly) in biologic-naïve patients with newly diagnosed, moderate- to high-risk CD...
September 22, 2023: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/37734801/diabetes-risk-and-provision-of-diabetes-prevention-activities-in-44-low-income-and-middle-income-countries-a-cross-sectional-analysis-of-nationally-representative-individual-level-survey-data
#33
JOURNAL ARTICLE
Nicholas Errol Rahim, David Flood, Maja E Marcus, Michaela Theilmann, Taing N Aung, Kokou Agoudavi, Krishna Kumar Aryal, Silver Bahendeka, Brice Bicaba, Pascal Bovet, Alpha Oumar Diallo, Farshad Farzadfar, David Guwatudde, Corine Houehanou, Dismand Houinato, Nahla Hwalla, Jutta Jorgensen, Gibson Bernard Kagaruki, Mary Mayige, Roy Wong-McClure, Bagher Larijani, Sahar Saeedi Moghaddam, Omar Mwalim, Kibachio Joseph Mwangi, Sudipa Sarkar, Abla M Sibai, Lela Sturua, Chea Wesseh, Pascal Geldsetzer, Rifat Atun, Sebastian Vollmer, Till Bärnighausen, Justine Davies, Mohammed K Ali, Jacqueline A Seiglie, Jennifer Manne-Goehler
BACKGROUND: The global burden of diabetes is rising rapidly, yet there is little evidence on individual-level diabetes prevention activities undertaken by health systems in low-income and middle-income countries (LMICs). Here we describe the population at high risk of developing diabetes, estimate diabetes prevention activities, and explore sociodemographic variation in these activities across LMICs. METHODS: We performed a pooled, cross-sectional analysis of individual-level data from nationally representative, population-based surveys conducted in 44 LMICs between October, 2009, and May, 2019...
October 2023: Lancet Global Health
https://read.qxmd.com/read/37707811/patient-reported-outcomes-of-omission-of-breast-surgery-following-neoadjuvant-systemic-therapy-a-nonrandomized-clinical-trial
#34
JOURNAL ARTICLE
Helen M Johnson, Heather Lin, Yu Shen, Emilia J Diego, Savitri Krishnamurthy, Wei T Yang, Benjamin D Smith, Vicente Valero, Anthony Lucci, Susie X Sun, Simona F Shaitelman, Melissa P Mitchell, Judy C Boughey, Richard L White, Gaiane M Rauch, Henry M Kuerer
IMPORTANCE: Patients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials. OBJECTIVE: To evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST)...
September 5, 2023: JAMA Network Open
https://read.qxmd.com/read/37703081/web-based-self-compassion-training-to-improve-the-well-being-of-youth-with-chronic-medical-conditions-randomized-controlled-trial
#35
RANDOMIZED CONTROLLED TRIAL
Amy Louise Finlay-Jones, Asha Parkinson, Fuschia Sirois, Yael Perry, Mark Boyes, Clare S Rees
BACKGROUND: Up to one-third of young people live with chronic physical conditions (eg, diabetes, asthma, and autoimmune disease) that frequently involve recurrent pain, fatigue, activity limitations, stigma, and isolation. These issues may be exacerbated as young people transition through adolescence. Accordingly, young people with chronic illness are at a high risk of psychological distress. Accessible, evidence-based interventions for young people with chronic illnesses are urgently needed to improve well-being, support adaptation, and enhance daily functioning...
September 13, 2023: Journal of Medical Internet Research
https://read.qxmd.com/read/37679742/sustainability-capacity-and-health-worker-normalisation-of-a-successful-non-communicable-disease-ncd-health-systems-intervention-within-primary-care-settings-in-uganda-a-quantitative-approach-to-a-qualitative-question
#36
JOURNAL ARTICLE
David Katende, Norah Nalweyiso, Gertrude Nabulime, Kevin Nakuya, Michael Charles Mubiru, Isaac Sekitoleko, Kathy Baisley, Moffat Nyirenda, Heiner Grosskurth
BACKGROUND: Interventions for non-communicable diseases are increasingly implemented and evaluated in sub-Saharan Africa, but little is known about their medium- to long-term sustainability beyond the end of research funding. A cluster randomised trial conducted between 2013 and 2016 in Uganda and Tanzania showed that an intervention package to improve hypertension (HT) and type-2 diabetes mellitus (DM) care was highly effective in increasing service readiness and quality of care. The present study assesses the sustainability of the intervention 4 years after the trial in Uganda...
September 7, 2023: BMC Health Services Research
https://read.qxmd.com/read/37643509/neuron-derived-extracellular-vesicles-to-examine-brain-mtor-target-engagement-with-sirolimus-in-patients-with-multiple-system-atrophy
#37
JOURNAL ARTICLE
Krishna A Pucha, Thong C Ma, William York, Un Jung Kang, Horacio Kaufmann, Dimitrios Kapogiannis, Jose-Alberto Palma
INTRODUCTION: Impaired autophagy is a pathogenic mechanism in the synucleinopathies. Sirolimus, a potent mTOR inhibitor and autophagy activator, had no beneficial effects in a randomized placebo-controlled trial in patients with multiple system atrophy (MSA). Whether sirolimus effectively inhibited brain mTOR activity was unknown. We aimed to evaluate if patients with MSA treated with sirolimus had evidence of inhibited brain mTOR pathways by measuring neuron-derived serum extracellular vesicles (NEVs)...
October 2023: Parkinsonism & related Disorders
https://read.qxmd.com/read/37585372/favorable-experience-of-transplant-strategy-including-liver-grafts-from-covid-19-donors-one-year-follow-up-results
#38
JOURNAL ARTICLE
Silvia Martini, Margherita Saracco, Donatella Cocchis, Fabrizia Pittaluga, Bruna Lavezzo, Francesca Barisone, Luigi Chiusa, Antonio Amoroso, Massimo Cardillo, Paolo A Grossi, Renato Romagnoli
BACKGROUND: Since November 2020, Italy was the first country to carry out a protocol and use liver from COVID-19 donors. We aimed to evaluate the medium-term outcome of patients who underwent liver transplant (LT) with those grafts. METHODS: We consecutively enrolled 283 patients who underwent first LT from November 2020 to December 2022 in our Center (follow-up 468 days). Twenty-five of 283 (8.8%, study population) received a graft from donors with previous (4%) or active (96%) SARS-CoV-2 infection, and 258/283 (91...
August 16, 2023: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://read.qxmd.com/read/37543519/relationship-between-lifestyle-habits-and-cardiovascular-risk-factors-in-familial-hypercholesterolemia
#39
JOURNAL ARTICLE
Laurie Dessureault, Gabrielle Roy, Patrick Couture, Anne Gangloff, Marta Guasch-Ferré, Louis Pérusse, Angelo Tremblay, Jean-Philippe Drouin-Chartier
BACKGROUND AND AIM: Little is known about the cardioprotective potential of a healthy lifestyle in familial hypercholesterolemia (FH). The objective of this study was to evaluate the relationship between lifestyle and cardiovascular risk factors in adults with FH. METHODS AND RESULTS: This cross-sectional study leveraged data from the CARTaGENE Quebec population-based cohort (Canada). Participants with FH were identified using the validated Simplified Canadian Definition for FH...
June 23, 2023: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://read.qxmd.com/read/37538264/omega-3-intake-is-associated-with-liver-disease-protection
#40
JOURNAL ARTICLE
Mara Sophie Vell, Kate Townsend Creasy, Eleonora Scorletti, Katharina Sophie Seeling, Leonida Hehl, Miriam Daphne Rendel, Kai Markus Schneider, Carolin Victoria Schneider
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease are among the most common liver diseases worldwide, and there are currently no Food and Drug Administration (FDA)-approved treatments. Recent studies have focused on lifestyle changes to prevent and treat NAFLD. Omega-3 supplementation is associated with improved outcomes in patients with chronic liver disease. However, it is unclear whether Omega-3 supplementation can prevent the development of liver disease, particularly in individuals at an increased (genetic) risk...
2023: Frontiers in Public Health
keyword
keyword
59433
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.